Additional immune checkpoints, such as TIM-3, LAG-3, and CTLA-4, have also been targeted, often in combination with anti-PD-1, showing effectiveness in some mouse glioma models [5, 9–13]. Here, HAVCR2 is linked to central nervous system cancer.